Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26597000 | 0.81 | HSP90AA1 (0.39) | HTTL3MBTL1NPC1HSP90AA1HPGD | |
| SCHEMBL18232751 | 0.81 | HTR3A (0.34) | SLC6A2HTTL3MBTL1NPC1HSP90AA1 | |
| SCHEMBL19678808 | 0.81 | KDM4E (0.41) | L3MBTL1HPGDKDM4EALDH1A1FEN1 | |
| SCHEMBL823082 | 0.79 | DYRK1A (0.50) | SLC6A2HTTL3MBTL1NPC1HSP90AA1 | |
| SCHEMBL12999395 | 0.78 | SLC6A2 (0.37) | SLC6A2HTTL3MBTL1NPC1HSP90AA1 | |
| SCHEMBL21140257 | 0.78 | HTR6 (0.41) | KDM4EELANE | |
| SCHEMBL7844045 | 0.77 | ELANE (0.57) | ELANEKDM4D | |
| SCHEMBL23106830 | 0.76 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL3213880 | 0.76 | SLC6A2 (0.43) | SLC6A2HTTL3MBTL1NPC1HSP90AA1 | |
| SCHEMBL20674508 | 0.74 | HTT (0.46) | SLC6A2HTTL3MBTL1NPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190194169-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | SLC6A2 3472/4885HTT 3438/4885L3MBTL1 4204/4885 |
| US-20190194169-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | SLC6A2 3564/4885HTT 3361/4885L3MBTL1 4264/4885 |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | SLC6A2 3037/4885HTT 3061/4885L3MBTL1 4459/4885 |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | SLC6A2 3037/4885HTT 3061/4885L3MBTL1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.